MC4R and obesity due to melanocortin 4 receptor deficiency: Current MC4R therapeutic peptides are of interest, but have been found to be anorexigenic and to stimulate erectile activity [36–38]; therefore, the development of therapies targeting monogenic obesity will need to circumvent such undesirable side effects.